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ultistep carcinogenesis involves more than six
discrete events also important in normal develop-
ment and cell behavior. Of these, local invasion
and metastasis cause most cancer deaths but are the least
well understood molecularly. We employed a combined
in vitro/in vivo carcinogenesis model, that is, polarized
Ha-Ras–transformed mammary epithelial cells (EpRas), to
dissect the role of Ras downstream signaling pathways in
epithelial cell plasticity, tumorigenesis, and metastasis.
Ha-Ras cooperates with transforming growth factor 
 
 
 
(TGF
 
 
 
) to cause epithelial mesenchymal transition (EMT)
 
characterized by spindle-like cell morphology, loss of
epithelial markers, and induction of mesenchymal markers.
EMT requires continuous TGF
 
 
 
 receptor (TGF
 
 
 
-R) and
oncogenic Ras signaling and is stabilized by autocrine
M
 
TGF
 
 
 
 production. In contrast, ﬁbroblast growth factors,
hepatocyte growth factor/scatter factor, or TGF
 
 
 
 alone induce
scattering, a spindle-like cell phenotype fully reversible after
factor withdrawal, which does not involve sustained marker
changes. Using speciﬁc inhibitors and effector-speciﬁc Ras
mutants, we show that a hyperactive Raf/mitogen-activated
protein kinase (MAPK) is required for EMT, whereas activation
 
of phosphatidylinositol 3-kinase
 
 
 
(PI3K) causes scattering and
protects from TGF
 
 
 
-induced apoptosis. Hyperactivation of the
PI3K pathway or the Raf/MAPK pathway are sufﬁcient for
tumorigenesis, whereas EMT in vivo and metastasis required
a hyperactive Raf/MAPK pathway. Thus, EMT seems to
be a close in vitro correlate of metastasis, both requiring
synergism between TGF
 
 
 
-R and Raf/MAPK signaling.
 
Introduction
 
Carcinomas are the most frequent type of malignancies in
humans. They arise by multistep mechanisms, involving five
to eight genetic alterations in dominant oncogenes or tumor
suppressor genes. These mutated genes cause alterations in
at least six types of cellular mechanisms, which cooperate to
generate a fully malignant carcinoma cell (for review see
Hanahan and Weinberg, 2000). Of these events, local inva-
sion and metastasis of tumor cells are the least well under-
stood at the molecular level, although metastases cause
 
 
 
90% of human cancer deaths. Particularly, it is unknown
which and how oncogenes or tumor suppressors cause
changes typical for invasive/metastatic cells such as loss or
altered functionality of cadherins (Christofori and Semb,
1999), CAMs (Perl et al., 1999), integrins, and their extra-
cellular matrix ligands (Lukashev and Werb, 1998), and
extracellular proteases and their inhibitors (Bergers and
Coussens, 2000). Except for E-cadherin (Christofori
and Semb, 1999), mutations in these genes themselves have
not been observed.
During normal development, tissue reorganization, wound
healing, and carcinogenesis, epithelial cells may transiently
or even stably lose epithelial polarity and acquire a mesen-
chymal phenotype. Depending on the cell model and type
of exogenous signal applied, these phenotypical changes
have been termed transformation, dedifferentiation, scatter-
ing, or epithelial mesenchymal transition (EMT). EMT is
relatively ill defined, always involving a change to a fibro-
blastoid spindle-shaped cell morphology, whereas changes in
epithelial/mesenchymal markers or gene expression may dif-
fer widely (for reviews see Hay, 1995; Thiery and Chopin,
1999). EMT is also still little understood in mechanistic
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terms and controversially discussed as to its importance for
carcinogenesis and metastasis (Boyer et al., 1996; Cui et al.,
1996; Bakin et al., 2000).
Transforming growth factor 
 
 
 
 (TGF
 
 
 
),* TGF
 
 
 
 receptor
(TGF
 
 
 
-R), and oncogenic Ras have been identified as im-
portant molecular players in EMT and metastasis (Oft et al.,
1996, 1998) using well-polarized mammary epithelial cells
(EpH4) (Reichmann et al., 1992) as a combined in vitro/in
vivo model. EpH4 cells are nontumorigenic and require low
amounts of TGF
 
 
 
 for organotypic tubular morphogenesis
in type I collagen gels, whereas higher TGF
 
 
 
 concentrations
induce cell cycle arrest and apoptosis (Oft et al., 1996). In
contrast, EpH4 cells transformed by oncogenic Ha-Ras
(EpRas) form rapidly growing tumors in mice and undergo
EMT in response to TGF
 
  
 
both in tumors and in collagen
gels, giving rise to mesenchymal-like cells (EpXT) in both
cases. These EpXT cells are characterized by a spindle-like
morphology and loss of epithelial and gain of mesenchymal
marker proteins, a phenotype stabilized by an autocrine
TGF
 
 
 
 loop in vitro and in vivo (Oft et al., 1996).
Further work revealed that TGF
 
 
 
-R signaling (Massague
and Wotton, 2000) was required for EMT, invasion in
vitro, and metastasis in vivo, using diverse murine and hu-
man cell systems (Oft et al., 1998). This tumor-promoting
role of TGF
 
 
 
 did not agree with either the known growth-
inhibitory tumor-suppressive function of TGF
 
 
 
 or inacti-
vating mutations of Smad4 or the TGF
 
 
 
-R in certain
cancers, suggesting a function of these genes as tumor sup-
pressors (Parsons et al., 1995; Schutte et al., 1996). How-
ever, more recent findings argue against TGF
 
 
 
 playing only
a tumor-suppressive role and suggest an additional tumor-
promoting role of TGF
 
 
 
 in late stage carcinogenesis (Cui et
al., 1996; Takaku et al., 1998; Onichtchouk et al., 1999).
These discrepancies may be explained by the fact that onco-
genic Ras renders cells insensitive to TGF
 
 
 
-induced cell cy-
cle arrest and apoptosis (Filmus et al., 1992; Oft et al., 1996;
Lehmann et al., 2000). However, it remains controversial by
which mechanisms Ras reverses TGF
 
 
 
-induced growth in-
hibition (Kretzschmar et al., 1999; Liu et al., 2000).
Similarly, the signaling pathways by which oncogenic Ras
contributes to EMT are discussed controversially. Different re-
ports implicated the mitogen-activated protein kinase (MAPK)
pathway (Chen et al., 2000), the phosphatidylinositol 3-kinase
(P13K) pathway (Bakin et al., 2000), or both (Potempa and
Ridley, 1998) in EMT-like processes, which, however, can also
be induced by TGF
 
 
 
 alone (Piek et al., 1999).
In this paper, we use the EpH4/EpRas cell system (Oft et
al., 1998) to dissect signaling pathways downstream of on-
cogenic Ras with respect to their ability to contribute to
EMT, tumorigenesis, and metastasis. Analysis of organo-
typic epithelial structures grown in collagen gels revealed
that EMT, a metastable process involving sustained loss of
epithelial and gain of mesenchymal markers (Reichmann et
al., 1992; Oft et al., 1996), can be distinguished from “scat-
tering,” which is fully reversible and does not involve major
epithelial/mesenchymal marker changes. Using both low
molecular weight inhibitors and expression of effector-spe-
cific Ras mutants (Rodriguez-Viciana et al., 1997), we show
that a hyperactive Raf/MAPK pathway is required for
TGF
 
 
 
-induced EMT, tumorigenesis, and metastasis. In
contrast, activation of the phosphatidylinositol 3-kinase
(PI3K) pathway is required for protection from TGF
 
 
 
-in-
duced apoptosis, allowing scattering but not EMT and caus-
ing tumors but not metastasis. Thus, EMT and metastasis
are closely linked processes, both relying on the synergism
between constitutive hyperactivation of the Raf/MAPK sig-
naling module and TGF
 
 
 
-R signaling.
 
Results
 
EMT and scattering: two distinct processes in epithelial 
plasticity induced by growth factors or oncogenes
 
In addition to oncogenic Ras (Oft et al., 1996), hepatocyte
growth factor (HGF)/scatter factor (SF), fibroblast growth
factor (FGF), and TGF
 
 
 
 alone induce mesenchymal features
in diverse epithelial cell systems (Brinkmann et al., 1995;
Piek et al., 1999; Thiery and Chopin, 1999). We investigated
whether these different signals would induce similar or differ-
ent types of mesenchymal phenotypes in EpRas cells. These
represent Ha-Ras–transformed fully polarized EpH4 cells
(Oft et al., 1996), spontaneously immortalized from mam-
mary glands of midpregnant mice (Reichmann et al., 1992).
EpRas cells were seeded in serum-free collagen gels and sub-
jected to different factor treatments. HGF/SF induced EpRas
cells to invade collagen gels and grow as disordered chords of
nonpolarized cells (Fig. 1 A; true for 
 
 
 
95% of 
 
 
 
100 struc-
tures counted in two to three separate collagen gels; see Mate-
rials and methods). Upon HGF/SF removal, 
 
 
 
90% of these
factor-induced disordered structures reverted to hollow tubu-
lar structures after an additional 5 d (Fig. 1 B). The disor-
dered collagen gel structures formed by the HGF/SF-treated
cells continued to express 
 
 
 
4-integrin, E-cadherin, and ZO-1
at the entire cell surface (indicating loss of polarity) and failed
to express vimentin (Fig. 1 C, left; unpublished data). Upon
factor withdrawal, 
 
 
 
4-integrin regained polarized basal ex-
pression in the hollow tubules formed (Fig. 1 C, right). Like-
wise, E-cadherin and ZO-1 were again expressed basolaterally
(Fig. 1 C, inset; unpublished data). Similar results were ob-
tained using FGF (unpublished data).
Controls using EpRas cells undergoing EMT in response to
TGF
 
 
 
 showed that the spindle-like phenotype induced by
TGF
 
 
 
 treatment (Fig. 1 A, inset) persisted after factor re-
moval (Fig. 1 B, inset) and involved loss of E-cadherin/
 
 
 
4-
integrin, whereas vimentin was strongly induced (Fig. 1 D,
left). Again, these marker changes persisted after TGF
 
 
 
 re-
moval (Fig. 1 D, right). These results show that HGF and
FGF reversibly induce a spindle-like migratory phenotype in
EpRas cells, which is characterized by loss of polarity but in-
volves no lasting changes in epithelial or mesenchymal marker
expression. We refer to this phenotype as scattering, since FGF
and HGF also induce “classical” scattering on plastic (unpub-
lished data), and distinguish it from EMT, which is not re-
 
*Abbreviations used in this paper: EMT, epithelial mesenchymal transi-
tion; Erk, extracellular signal–regulated kinase; FGF, fibroblast growth
factor; HGF, hepatocyte growth factor; MAPK, mitogen-activated pro-
tein kinase; PI3K, phosphatidylinositol 3-kinase; SF, scatter factor;
TGF
 
 
 
, transforming growth factor 
 
 
 
;
 
 
 
TGF
 
 
 
-R, TGF
 
 
 
 receptor. 
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versed upon factor removal and involves stable loss of epithe-
lial markers and upregulation of mesenchymal markers.
To answer the question if and how TGF
 
 
 
 alone (Piek et al.,
1999) would alter the phenotype of nontransformed EpH4
cells, we used EpH4 cells expressing a retrovirally transduced
antiapoptotic Bcl-2 protein. This was necessary since doses of
TGF
 
 
 
 (2–5 ng/ml) causing EMT in EpRas cells induced
growth arrest and apoptosis in EpH4 cells. In the absence of
TGF
 
 
 
, the Bcl-2–expressing EpH4 cells formed tubular
structures in collagen gels similar to EpH4 control cells (Fig.
1, E compared with F). When treated with TGF
 
 
 
, the
EpH4–Bcl-2 cells were apoptosis protected as expected (8%
TUNEL-positive cells; Fig. 1 G, inset) and formed disordered
structures consisting of migratory cells (Fig. 1 G), whereas
control EpH4 cells underwent apoptosis (48% TUNEL-posi-
tive cells; Fig. 1 E, inset). However, in contrast to EpRas cells
the TGF
 
 
 
-treated Bcl-2–expressing EpH4 cells reverted to
hollow tubular structures 4 d after TGF
 
 
 
 removal (Fig. 1 H).
Likewise, they maintained E-cadherin expression throughout
the experiment, whereas vimentin expression was not detect-
able (unpublished data). In conclusion, TGF
 
 
 
 causes revers-
ible scattering in EpH4 cells apoptosis protected by Bcl-2 but
fails to induce EMT in the absence of oncogenic Ras, suggest-
ing that Ras induces an EMT competent state in addition to
prevent TGF
 
 
 
-induced apoptosis.
 
Active oncogenic Ras is required for both induction 
and maintenance of EMT
 
Using a kinase-dead dominant negative mutant of the
TGF
 
 
 
-RII, we showed previously that maintenance of
TGF
 
 
 
-R signaling is required for EMT and metastasis (Oft
et al., 1998). To address if EMT also required maintenance
Figure 1. Scattering induced by scatter factor (HGF/SF) and TGF  can be distinguished from EMT by reversibility and lack of marker 
changes. (A–D) EpRas collagen gel structures were treated with SF/HGF and TGF . (A) EpRas cells seeded in collagen gels for 3 d were 
treated with HGF/SF or TGF  (insets) for an additional 5 d and photographed (B). After factor removal, (as described in Materials and meth-
ods) cells were maintained for an additional 4 d and photographed again. White arrows indicate lumina of tubular structures; black arrows indicate 
unordered strands of spindle-like invasive cells. (C and D). Structures treated as in A and B were fixed, stained with antibodies to the epithelial 
markers  4-integrin, E-cadherin, and ZO-1 (C, insets) and the mesenchymal marker vimentin, and analyzed by confocal immunofluorescence 
microscopy (as described in Materials and methods). (C) Structures transiently treated with HGF/SF. (D) Structures transiently treated with 
TGF . Note that HGF/SF-treated cells retain nonpolar distributed  4-integrin (C, left), whereas cells completely repolarize after HGF/SF 
removal (basolateral localized E-cadherin, and ZO-1) (C, left and inset). In contrast, the TGF -treated control structures undergo EMT (loss of 
 4-integrin, and vimentin expression) (D, left), persisting after TGF  withdrawal (D, right). (E–H) Bcl-2–expressing EpH4 cells (Ep–Bcl-2) and 
control EpH4 cells were treated with TGF , which induced apoptosis (revealed by in situ TUNEL staining) in the EpH4 cells (E, inset) but a 
spindle cell-like morphology (G) and no apoptosis in the Ep–Bcl-2 cells (G, inset). Untreated cells of both types form normal hollow tubules 
(E and F). After withdrawal of TGF , the EpH4–Bcl-2 cells revert to tubular structures (H). Bars: (A, B, and E–H) 50  m; (C and D) 10  m. 
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Figure 2.
 
Ras activity is required for induction and maintenance of EMT. 
 
(A–D) EpXT cells were seeded into collagen gels in the absence 
(A) or presence (B) of 10 
 
 
 
M Ras farnesylation inhibitor (L739749), and resulting structures were photographed after 6 d (as described in 
Materials and methods). Note the complete reversal of EpXT cells to tubular structures with lumina (white arrows), which persisted after 
removal of the inhibitor for 4 d (C). The inhibitor alone did not affect tubular structures formed by EpRas cells (B, inset) or after reversal (D, 
inset, control), whereas treatment of the reverted structures with TGF
 
 
 
 plus L739749 caused cell disintegration. (E and F) Immunostaining of 
frozen ultrathin sections of EpXT collagen gel structures before (E) or after treatment (F) with L739749 for 5 d. Sections were stained with  
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of oncogenic Ras activity, we used a specific nontoxic inhibi-
tor of Ras-farnesylation (L739749 [Kohl et al., 1994]).
L739749 reversed EMT in mesenchymal EpXT cells, causing
reformation of hollow tubular structures (Fig. 2 B) from the
unordered cords and strands of EpXT cells (Fig. 2 A) but did
not affect EpH4 (Fig. 2 B, inset). After inhibitor withdrawal,
the reverted cells maintained their polarized phenotype as in-
dicated by persistence of tubular structures (Fig. 2 C). How-
ever, these structures could be reinduced to undergo EMT
when again treated with TGF
 
 
 
 (unpublished data). This in-
dicates that Ras inhibition reversed EMT completely, con-
verting EpXT cells into cells with EpH4 cell properties. In
line with this, reactivation of Ras in the reverted cells was in-
sufficient for EMT, again requiring TGF
 
 
 
 as in the original
EpRas cells (Oft et al., 1996). Furthermore, cotreatment of
the reverted cells with L739749 and TGF
 
 
 
 resulted in cell
death (Fig. 2 D), whereas their treatment with Ras inhibitor
alone caused no phenotypical changes (Fig. 2 D, inset).
These results were confirmed by analyzing marker ex-
pression, using ultrathin cryosections stained with respec-
tive fluorescent antibodies (see Materials and methods)
from similar collagen gel structures as shown in Fig. 2, A
and B. As expected, the mesenchymal chords of untreated
EpXT cells expressed vimentin and intracellular TGF
 
 
 
(Fig. 2 E, top) and deposited fibronectin extracellularly
(periphery of structures and intercellular spaces; Fig. 2 E,
bottom). After treatment with L739749 for 5 d (Fig. 2 F),
vimentin and TGF
 
 
 
 expression was no longer detectable
in the hollow structures obtained (Fig. 2 F, top). Two ad-
ditional mesenchymal markers, CD68 (macrosialin) and
calgranulin A, were also downregulated (unpublished
data). Furthermore, the L739749-treated cells reexpressed
the tight junction marker ZO-1 (Fig. 2 F, bottom) and
E-cadherin (unpublished data) in a polarized basolateral
fashion. The presence of tight junctions in the epithelial
tubules induced by L739749 were confirmed by EM, using
immunogold staining for ZO-1, although the mesenchy-
mal chords obtained in the absence of inhibitor failed to
show any junction-like structures (unpublished data).
In conclusion, inhibition of Ras in EpXT cells completely
restores a normal polarized epithelial phenotype, indicating
that sustained oncogenic Ras and TGF
 
 
 
-R signaling are re-
quired for induction and maintenance of EMT in EpRas cells.
 
Ras downstream signaling required for EMT: analysis 
by low molecular weight inhibitors
 
Oncogenic Ha-Ras activates multiple downstream signal
transduction pathways, including the Raf/MAPK module
and the PI3K-PKB/Akt pathway (for review see Rommel
and Hafen, 1998). Both pathways were implied in cell trans-
formation in vitro (Rodriguez-Viciana et al., 1997) and tu-
morigenesis (Webb et al., 1998). To dissect Ras-activated
downstream pathways required for different aspects of Ha-
Ras transformation in epithelial cells (EMT, scattering, and
apoptosis protection), we employed two specific low molec-
 
ular weight inhibitors selectively blocking either the MAPK
pathway (PD98059) or PI3K signaling (LY294002).
The activity of the Mek1/MAPK- and PI3K-PKB/Akt
pathways in EpRas and EpH4 cells and the ability of the two
inhibitors to selectively suppress either pathway was ana-
lyzed by Western blots using phospho-specific antibodies to
MAPK/extracellular signal–regulated kinase (Erk)1/2 and
PKB/Akt. EpRas cells exhibited strongly elevated phospho-
Erk/MAPK and phospho-PKB/Akt levels compared with
EpH4 cells (Fig. 3 A, lanes E and R). These elevated levels
were largely independent of cell density (unpublished data).
Testing of the inhibitors in EpRas cells revealed that 10 
 
 
 
M
PD98059 reduced MAPK phosphorylation to basal levels,
whereas 40 
 
 
 
M completely abolished MAPK phosphoryla-
tion (unpublished data). Conversely, PKB/Akt phosphoryla-
tion levels were not affected by PD98059 (Fig. 3 A, left,
lanes R and iR; unpublished data). Conversely, 5 
 
 
 
M
LY294002 added at 12-h intervals stably reduced elevated
PKB/Akt phosphorylation in EpRas cells to basal levels (Fig.
3 A, middle; unpublished data), whereas 30 
 
 
 
M LY294002
essentially abolished PKB/Akt phosphorylation (Fig. 3 A,
right). In contrast, even high levels of LY294002 had no ef-
fect on MAPK phosphorylation in EpRas cells (Fig. 3 A).
Next, we analyzed the effects of the two inhibitors on
TGF
 
 
 
-induced EMT in collagen gels (Fig. 3 B, top). 10 
 
 
 
M
PD98059 prevented EMT in 
 
 
 
95% of the structures, giv-
ing rise to hollow tubules (Fig. 3 B, top) typical for control
EpRas cells (Fig. 3 A, inset). These inhibitor-treated struc-
tures failed to express vimentin while retaining E-cadherin
(unpublished data). In contrast, 5 
 
 
 
M LY294002 did not af-
fect TGF
 
 
 
-induced EMT in EpRas cells (Fig. 3 B, bottom
left; unpublished data), whereas 30 
 
 
 
M LY294002 (almost
completely suppressing PI3K signaling; Fig. 3 A) caused cell
disintegration (Fig. 3 B, bottom right). None of the inhibi-
tors strongly altered formation of hollow structures in the
absence of TGF
 
 
 
, showing that they were nontoxic at the re-
spective concentrations used (Fig. 3, A–D, insets).
The disintegration of EpRas cells observed after treatment
with 30 
 
 
 
M LY294002 plus TGF
 
 
 
 was clearly due to strongly
increased apoptosis as shown by TUNEL staining or dye exclu-
sion (Fig. 3, C and D; see Materials and methods). In contrast,
10 
 
 
 
M PD98059 or 5 
 
 
 
M LY294002 plus TGF
 
  
 
and
LY294004, PD98059, or TGF
 
 
 
 added alone failed to signifi-
cantly increase apoptosis (Fig. 3, C and D; unpublished data).
In conclusion, high levels of Mek1/MAPK activity are neces-
sary for induction and maintenance of EMT. Similar elevated
levels of PI3K pathway activity are required for protection
from TGF
 
 
 
-induced apoptosis but not for EMT.
 
Effector-specific Ras mutants in vitro: MAPK 
hyperactivation is required for EMT, whereas PI3K 
signaling causes scattering
 
To verify these results by an independent approach, two well-
characterized Ras mutants were used, which selectively signal
along the MAPK pathway, S35-V12–Ras (S35-Ras), or the
 
antibodies to TGF
 
 
 
 (red) (Oft et al., 1996) and vimentin (green) plus DAPI (top, DNA). Parallel sections (bottom) were stained with antibodies 
to ZO-1 (red) and fibronectin (green). L739749 causes loss of intracellular TGF
 
 
 
 and vimentin (top) and extracellular fibronectin (bottom) and 
reexpression of ZO-1 at apicolateral sites of tight junctions (blue arrows, bottom left). Bars: (A–D) 50 
 
 
 
m; (E and F) 20 
 
 
 
m. 
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PI3K pathway, C40-V12–Ras (C40-Ras), due to specific
amino acid changes in the effector loop of the Ras protein
(Rodriguez-Viciana et al., 1997; Downward, 1998). These
mutant proteins and the parental oncogenic Ras protein
(V12-Ras) were overexpressed in EpH4 cells using respective
retroviral constructs (see Materials and methods). Since V12-
Ras did not reach similar expression levels in mass cultures as
seen for v-H-Ras in EpRas cells (unpublished data), clones
were selected expressing particularly high levels of V12-Ras,
S35-Ras, and C40-Ras. In Western blots, S35-Ras–express-
ing clones showed elevated phosphorylation of Erk1 but only
basal levels of PKB/Akt phosphorylation compared with
empty vector controls. In contrast, the C40-Ras clones
showed only basal level phosphorylation of Erks but elevated
levels of PKB/Akt phosphorylation (Fig. 4 A). As expected,
the V12-Ras control cells showed elevated levels of both
phospho-Erk and phospho-PKB/Akt. Similar results were
obtained with pools of 
 
 
 
10 clones also selected for high level
expression of V12-Ras, S35-Ras, and C40-Ras proteins (Fig.
4 B; unpublished data; see Materials and methods).
The Ras mutant-overexpressing clones (Fig. 4 A) were
then characterized for their response to TGF
 
 
 
. On porous
supports (filters) allowing epithelial polarization, treatment
of control V12-Ras cells and two S35-Ras–overexpressing
clones with TGF
 
 
 
 for 7 d resulted in spindle-shaped, vimen-
tin-positive, E-cadherin–negative cells (Fig. 4 C; unpub-
lished data). In contrast, C40-Ras–overexpressing cells failed
to lose E-cadherin or to upregulate vimentin but showed loss
of polarity (redistribution of E-cadherin; Fig. 4 C). As ex-
pected, control cells not treated with TGF
 
 
 
 always expressed
lateral E-cadherin and no vimentin (Fig. 4 C, insets).
In collagen gels, untreated S35-Ras cells resembled V12-Ras
cells (e.g., forming distended tubular structures with large lu-
mina in collagen gels), whereas C40 cells more closely resem-
Figure 3. Inhibitors of Mek-1 prevent and reverse EMT, and PI3K inhibitors abolish protection from TGF -induced apoptosis. (A) EpH4 
cells (lanes marked E) or EpRas cells mock treated (lanes marked R) or treated with the inhibitors indicated (lanes marked iR) were lysed after 
6 h of inhibitor treatment and analyzed for serine phosphorylation of Erk1/2 (MAPK) and PKB/Akt in Western blots (as described in Materials 
and methods). (B) EpRas cells seeded into collagen gels in the presence or absence (insets) of 5 ng/ml TGF . Both types of cultures were then 
left untreated (top, control) or treated with PD98059 (top right) and LY294002 (bottom) for another 5 d (as described in Materials and methods). 
Neither inhibitor was toxic to EpRas cells without TGF  (insets; LY294002 slowed down structure growth). PD98059 (10  M) completely 
reverted EMT (white arrows, top right), 5  M LY294002 had no effect on the mesenchymal structures (black arrows, bottom left), whereas 30 
 M caused cell death (bottom right, red circle). (C) Confocal analysis of in situ TUNEL staining (green) performed on collagen gel structures 
from EpRas cells treated for 4 d as indicated on the microphotographs (counterstaining for DNA in blue). (D) Quantitative analysis of cell 
death caused by inhibition of MEK-1 and PI3K in the absence or presence of TGF  using trypan blue dye exclusion assay. The percentages of 
structures consisting of 25–60% (hatched bars, partially dead) or  60% trypan blue–positive cells (black bars, dead) are shown (as described 
in Materials and methods). Red asterisks indicate statistically significant induction of apoptosis by TGF . Bars: (B and C) 50  m. 
MAPK and TGF
 
 
 
 cooperate to induce metastasis |
 
 Janda et al. 305
 
bled EpH4 cells (thin tubules with tiny lumina; Fig. 5 A, top).
Marker staining revealed basolateral E-cadherin staining and
no expression of mesenchymal markers in all three cell types
(Fig. 5 B, insets; unpublished data). Treatment of V12-Ras,
S35-Ras, and C40-Ras cells with TGF
 
 
 
 resulted in unordered
cell strands and cords with spindle-like cellular morphology
(Fig. 5 A, middle). After withdrawal of TGF
 
 
 
, these lumen-
less disordered structures persisted in the V12-Ras and S35-
Ras cells, whereas C40-Ras cells reverted to thin hollow struc-
tures (Fig. 5 A, bottom). Likewise, TGF
 
 
 
-treated S35-Ras
cells showed loss of E-cadherin/
 
 
 
4-integrin staining and in-
duction of the mesenchymal markers vimentin and CD68
(Fig. 5 B, top), a marker distribution persisting after removal
of TGF
 
 
 
 (Fig. 5 B, bottom). In contrast, C40-Ras–expressing
cells maintained nonpolar E-cadherin staining in the disor-
dered structures induced by TGF
 
 
 
, whereas mesenchymal
markers remained undetectable (Fig. 5 B, top). Upon with-
drawal of TGF
 
 
 
, the C40-Ras structures regained epithelial
polarity as indicated by lumen formation and basolateral
E-cadherin staining (Fig. 5 B, bottom).
In conclusion, a hyperactive MAPK/Erk pathway plus
TGF
 
 
 
 is sufficient to cause EMT, whereas elevated PI3K
signaling plus TGF
 
 
 
 induces scattering, that is, spindle-
shaped cells without loss of epithelial and gain of mesenchy-
mal markers.
 
Effector-specific Ras mutants: protection from
TGF
 
 
 
-induced apoptosis requires PI3K signaling
 
Oncogenic Ras and Raf abolish TGF
 
 
 
-induced apoptosis in
several epithelial cell systems (Oft et al., 1996; Lehmann et al.,
2000). V12-Ras, S35-Ras, and C40-Ras cells (from both
clones and clone pools; Fig. 4 A) were therefore tested for
their apoptotic response upon TGF
 
 
 
 treatment. This was
done using cells pregrown in collagen gels for 3–4 d (Fig. 6
A), since detection of apoptosis was much easier in these cul-
tures than on plastic (Lehmann et al., 2000). Collagen struc-
tures were either collagenase digested and the cells subjected
to TUNEL staining in suspension (Fig. 6 C, top) or TUNEL
stained and counted in situ, that is, within the intact collagen
gels (Fig. 6, B and C, bottom; see Materials and methods).
Both approaches yielded similar results. Already at low
TGF
 
 
 
 levels (1 ng/ml), apoptosis of EpH4 control cells was
enhanced significantly, whereas 
 
 
 
95% of these cells were
TUNEL positive and thus apoptotic at 5 ng/ml TGF
 
 
 
 (Fig.
6 C). EpH4 cells expressing V12-Ras and C40-Ras showed
no significant elevation of apoptotic cells even at high TGF
 
 
Figure 4. Biochemical and biological characterization of EpH4 cells expressing Ras effector-specific mutants lacking signaling along the 
MAPK or PI3K pathways. (A) Clones of EpH4 cells expressing the Ras effector mutants S35-Ras, C40-Ras, or V12-Ras were tested for overexpression 
of Ras proteins in Western blots using V12-Ras–specific antibodies. Clones highly overexpressing the exogenous Ras proteins (top) were then 
tested for levels of phospho-Erk (middle) or phospho-Akt (bottom) by respective phospho-specific antibodies (as described in Materials and 
methods). (B) Mass cultures (pools of multiple clones) expressing lower but still clearly elevated levels of H-V12–Ras or Ras effector mutant 
proteins S35 or C40 (unpublished data) were analyzed for phospho-Erk and phospho-Akt expression as in A. (C) Representative clones 
expressing V12-Ras (left), S35-Ras (middle), and C40-Ras (right) were cultivated on porous supports for 7 d in the presence (panels) or 
absence of TGF  (insets). Cells were immunostained for E-cadherin (green) and vimentin (red) plus DAPI counterstaining for DNA (blue; as 
described in Materials and methods) and analyzed by confocal immunofluorescence microscopy. Bars, 20  m.306 The Journal of Cell Biology | Volume 156, Number 2, 2002
concentrations. In contrast, S35-Ras cells were consistently
sensitive to TGF -induced apoptosis but required higher
TGF  levels for complete apoptosis than EpH4 cells (Fig. 6,
B and C). Thus, hyperactivation of the PI3K pathway is re-
quired for protection from TGF -induced apoptosis. In
contrast, hyperactive MAPK signaling in S35-Ras cells failed
to induce apoptosis protection at higher TGF  levels.
Effector-specific Ras mutants in vivo: elevated 
MAPK and PI3K signaling are each sufficient 
for tumor formation
To analyze the importance of Ras downstream signaling
pathways for tumor formation in vivo, clones strongly over-
expressing V12-Ras, S35-Ras, and C40-Ras were injected
into the mammary gland fat pads of nude mice. All cell types
caused tumors with comparable efficiencies (16/16 injection
sites; Fig. 7 A). Similar results were obtained with respective
pools of clones overexpressing the different Ras signaling
mutants except that tumor formation by cells from S35-Ras
clone pools was significantly slower than from respective
C40-Ras clone pools (unpublished data). Bcl-2–EpH4 con-
trol cells formed similarly small regressing nodules as EpH4
cells, which contained only well-polarized, E-cadherin–posi-
tive, vimentin-negative cells (unpublished data). Therefore,
protection of EpH4 cells from TGF -dependent apoptosis
is not sufficient for tumorigenesis.
To address which phenotypic changes of the Ras mutant-
expressing cells accompanied tumor growth, we recultivated
cells from 4–5-wk-old tumors, using G418 to select for ex-
tumor cells of donor origin (see Materials and methods) and
analyzed them for E-cadherin and vimentin expression by
immunofluorescence. These ex-tumor cells closely resem-
bled the respective Ras mutant-expressing cells subjected to
TGF  treatment in vitro (Fig. 4 C compared with Fig. 7 B).
V12-Ras and S35-Ras ex-tumor cells showed a typical spin-
dle-shaped morphology (unpublished data) and were vi-
mentin-positive and E-cadherin–negative (Fig. 7 B, left and
middle). In contrast, the C40-Ras ex-tumor cells showed
Figure 5. EpH4 cells expressing V12-Ras 
or S35-Ras undergo EMT upon TGF  
treatment; C40-Ras cells undergo 
scattering. (A) EpH4 cell clones over-
expressing V12-Ras (left) and the Ras 
effector mutants S35-Ras (middle) and 
C40-Ras (right; Fig. 4) were seeded in 
collagen gels and either left untreated 
(top) or treated (middle) with 5 ng/ml 
TGF  for 5 d followed by removal of 
TGF  and further cultivation for 5 d 
(bottom). Photographs of representative 
tubular structures with lumina (white 
arrows) or distended chords and strands 
of invasive cells with mesenchymal 
morphology (black arrows) are shown. 
(B) Similar collagen gel structures as in A 
were stained in situ with antibodies to 
epithelial markers (green,  4-integrin 
and E-cadherin) and mesenchymal 
markers (red, vimentin and CD68; as 
described in the text) and analyzed by 
confocal immunofluorescence micros-
copy (as described in Materials and 
methods). (Top left, insets) tubular struc-
tures formed by untreated S35-Ras cells. 
(Top) “Invasive” structures formed by 
S35-Ras and C40-Ras cells after TGF  
treatment (note the persistent nonpolar-
ized expression of epithelial markers in 
the C40-Ras structures). (Bottom) Struc-
tures formed by S35-Ras and C40-Ras 
after removal of TGF  (mesenchymal 
shape and mesenchymal markers persist 
in the S35-Ras cells; C40-Ras cells revert 
to tubular structures with lumina [white 
dotted lines] basolaterally expressed 
epithelial markers). Bars: (A) 50  m; (B) 
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epithelioid morphology (unpublished data) and E-cadherin
staining, whereas vimentin was undetectable. In conclusion,
the separate activation of either the PI3K pathway or the
MAPK pathway is sufficient to confer tumorigenic potential
to EpH4 cells, whereas EMT in vivo requires the MAPK
pathway (see Discussion).
Effector-specific Ras mutants in vivo: only hyperactive 
MAPK can induce metastasis
Finally, we sought to determine whether or not V12-Ras–,
S35-Ras–, or C40-Ras–expressing cells were able to form
metastases. In line with metastasis formation in nude mice
being a rare event (McClatchey, 1999), EpRas-derived
primary tumors rarely progressed to metastasis before kill-
ing the animal. Resection of primary tumors to allow for
late metastasis formation met with technical difficulties.
Therefore, ex-tumor cells derived from two clones of S35-
Ras cells and one clone each of C40-Ras and V12-Ras
cells were injected into the tail veins of nude mice, an as-
say testing for survival of injected cells in the circulation
and for evasation and colonization of distant organs. Most
of the mice injected with V12-Ras or S35-Ras cells died
between 2 and 5 wk, whereas all C40-Ras–injected mice
survived until the end of the experiments (10 wk; Fig. 8
A). Upon histological analysis, the lungs of dead or mori-
bund animals injected with V12-Ras or S35-Ras cells
showed multiple metastases in all cases, often surrounded
by blood vessels (Fig. 8 B, left). In contrast, lungs from
C40-Ras–EpH4 injected animals were histologically free
of metastases (Fig. 8 B, right), and no metastases were
found in other organs (unpublished data). Similar results
were obtained using pooled clones of V12-Ras–, S35-Ras–,
or C40-Ras–EpH4 cells except that the S35-Ras cell-derived
metastases appeared much later in line with the slower
growth rate of the respective primary tumors (unpublished
data).
These results indicate that metastasis formation seems to
depend entirely on hyperactivity of the Raf/MAPK pathway,
whereas a hyperactive PI3K pathway (in C40-Ras cells) is
not sufficient for metastasis formation.
Figure 6. V12-Ras and C40-Ras but not S35-Ras protect EpH4 cells from TGF -induced apoptosis. (A) For apoptosis determination in collagen 
gels, EpH4 cells expressing Ras or Ras effector–specific mutants were allowed to form structures in collagen gels for 3 d and were treated with 
various concentrations of TGF  (0.5–40 ng/ml) for 4 d (dotted bar). Cells were either TUNEL stained in suspension (C, top) or in situ (B, and C, 
bottom panel; as described in Materials and methods). (B) Confocal immunofluorescence analysis of gel structures formed by clones overexpressing 
S35-Ras (left) and C40-Ras cells (right) treated with moderate (top, 2.5 ng/ml) or high levels of TGF  (40 ng/ml; see A) and subjected to in situ 
TUNEL staining (green). DAPI staining (blue) indicates live cells. (C) Quantitation of TUNEL-positive cells from collagen gel structures either 
stained and counted in suspension after collagenase digestion (top; red asterisks indicate statistically significant increases in apoptosis induced 
by TGF ) or stained and counted in situ (bottom; as described in Materials and methods). Mean percentages of apoptotic cells from multiple 
gel structures plus standard deviations (error bars) from three independent determinations are shown. Bars, 50  m.308 The Journal of Cell Biology | Volume 156, Number 2, 2002
Discussion
In this paper, we utilize a well-characterized combined in
vitro/in vivo model of mammary carcinogenesis (EpRas) to
address the role of distinct Ras downstream signaling path-
ways in epithelial plasticity, tumorigenesis, and metastasis.
We show that Ras-dependent hyperactive signaling of the
Raf/MAPK pathway is required for EMT, whereas Ras acti-
vation of the PI3K pathway causes scattering and is required
for protection from TGF -induced apoptosis. In vivo, a hy-
peractive PI3K pathway correlated with tumor formation,
whereas a hyperactive MAPK pathway caused both tumors
and metastasis. Thus, activation of two different Ras down-
stream signaling pathways during tumorigenesis and me-
tastasis cause two clearly distinct changes toward a motile
phenotype, only one of which (EMT) is associated with
metastatic potential.
EMT and scattering, two distinct aspects 
of epithelial plasticity
Our work and work by others have established several opera-
tional criteria for EMT. These are (a) a requirement for co-
operation of a hyperactive MAPK–Erk1/2 pathway with
TGF -R signaling, (b) metastability, that is, persistence of
the EMT phenotype after removal of TGF , and (c) drastic
long-lasting molecular changes such as loss of E-cadherin
and a switch to a mesenchymal gene expression pattern (Oft
et al., 1996; Eger et al., 2000; Lehmann et al., 2000). These
criteria apply only partially to epithelial plasticity changes
(often also termed EMT) observed by others in different cell
systems in response to Ras alone (Chen et al., 2000), Ras or
Raf plus TGF  (Oft et al., 1998; Lehmann et al., 2000),
FGF, EGF, and SF/HGF (Thiery and Chopin, 1999; Boyer
et al., 2000), and finally TGF  alone (Piek et al., 1999;
Bakin et al., 2000). These systems differ widely with respect
to reversibility and switch from an epithelial to a mesenchy-
mal gene expression program, their common denominator
being morphological changes to a spindle-like phenotype.
These discrepancies may be explained by one major find-
ing of this paper, showing that different signals can cause
qualitatively different alterations of epithelial plasticity in
the same cell type. In EpH4 cells, Ras or upstream receptor
tyrosine kinases (e.g., activated HER2; unpublished data)
plus TGF  caused EMT. In contrast, HGF, FGF, or TGF 
alone caused scattering in apoptosis-protected EpH4 cells.
Scattering involves a similar spindle-like migratory pheno-
Figure 7. S35-Ras– and C40-Ras–overexpressing cells form tumors, but only S35-Ras cells undergo EMT in vivo. (A) Various clones (see 
also Fig. 4 A) overexpressing V12-Ras (black symbols) S35-Ras (red symbols) and C40-Ras (blue symbols) were injected into the mammary 
gland fat pads of mice (four mice with a total of 16 injection sites per clone). Growth of the multiple tumors developing in all mice was 
followed by measuring mean tumor sizes (as described in Materials and methods). (B) Ex-tumor cells recultivated from 4–5-wk-old tumors 
(as described in Materials and methods) induced by V12-Ras, S35-Ras, and C40-Ras clones (A) were seeded onto porous supports and 
analyzed by immunostaining for E-cadherin (green) and vimentin (red). Blue, DAPI counterstain for DNA. Bars, 20  m.MAPK and TGF  cooperate to induce metastasis | Janda et al. 309
type as EMT but involves only transient gene expression
changes and is fully reversible. Thus, it is possible that some
of the various types of epithelial plasticity termed EMT by
others (see above) may correspond to scattering rather than
EMT or represent hybrid phenotypes. Scattering may also
occur during the initial stages of organotypic tubule forma-
tion in collagen gels (unpublished data), perhaps corre-
sponding to tissue remodeling during outgrowth of glan-
dular epithelial cells apparently dependent on PI3K plus
Mek1/Erk signaling (Khwaja et al., 1998).
Multiple functions of Ras during 
EMT and tumorigenesis
Oncogenic Ras, the second player in EMT, displays diverse
functions in EpH4 cells. First, Ras protects EpH4 cells from
apoptosis, both by upregulation of PI3K and by downregu-
lation of Fas receptor, rendering the cells refractory to Fas
ligand (Peli et al., 1999). Second, oncogenic Ras or Raf
alone cause more plastic cell–cell contacts, increased migra-
tion, and distended tubular or alveolar structures with large
lumina in collagen gels (Oft et al., 1996; Lehmann et al.,
2000). These changes may be due to Ras-dependent upregu-
lation of N-cadherin expression in EpH4 cells, which func-
tionally substituted for E-cadherin and contributed to the al-
tered behavior of EpRas cells (unpublished data). In line
with this, N-cadherin regulates cell motility and invasiveness
during development and in various carcinoma cell lines (Ra-
dice et al., 1997; Nieman et al., 1999).
Importantly, even strongly overexpressed oncogenic Ras
does not abolish epithelial polarity and organotypic structure
formation on its own in several epithelial cell types (Lehmann
et al., 2000; Gotzmann et al., 2002). The evidence from oth-
ers with respect to this issue is controversial. In MDCK cells,
Ras either caused loss of E-cadherin and ZO-1 expression and
change to a fibroblastic morphology (Chen et al., 2000) or a
partial loss of epithelial polarity, maintaining intact, tight, and
adherent junctions (Schoenenberger et al., 1991). These dis-
crepancies, probably due to heterogeneity of the MDCK cells
studied or effects by TGF  present in serum, underline the
importance of using cell systems, which form organotypic epi-
thelial structures under serum-free conditions where levels of
TGF  and other factors can be strictly controlled.
On the other hand, TGF -dependent EMT required
strong overexpression of oncogenic Ras. This was shown in
Figure 8. S35-Ras– but not C40-Ras–overexpressing EpH4 cells form lung metastases upon tail vein injection. (A) Ex-tumor cells from the 
V12-Ras (black symbols), S35-Ras (red symbols), and C40-Ras clones (blue symbols) indicated were injected intravenously into four nude 
mice per cell type. Moribund mice were killed and analyzed for the presence of lung metastases. The two surviving mice injected with S35-Ras 
clones were killed at day 55 and also contained lung metastases. None of the four mice injected with C40-Ras cells (killed after 10 wk) 
showed any lung metastases. (B) Histological stainings of sections from lungs of uninjected animals (left) and S35-Ras (middle) and 
C40-Ras–injected mice (two animals each). Note large metastases (also around blood vessels) only in the S35-Ras–injected mice. Bar, 100  m.310 The Journal of Cell Biology | Volume 156, Number 2, 2002
cells expressing low or intermediate Ras levels, which are
protected from apoptosis and undergo scattering but not
EMT in response to TGF  (unpublished data). The same
was true for saturating doses of TGF  (1  g/ml) when
added to EpH4 cells together with standard doses of TGF 
(unpublished data). These findings raise the question
whether EMT requires sustained nuclear translocation of
MAPK, occurring during neuronal differentiation of PC12
cells induced by overexpressed receptor tyrosine kinases
(Traverse et al., 1994). It is also unclear which endogenous
pathways cooperate with TGF  family ligands when EMT
is induced during development (Sun et al., 2000).
Dissection of Ras downstream signaling
A second important finding of our paper was that hyperacti-
vation of the Raf/MAPK pathway caused EMT in vitro, and
in vivo tumor formation and metastasis. Respective activa-
tion of the PI3K pathway was sufficient for tumorigenesis
but not metastasis, causing both scattering and protection
from TGF -induced apoptosis. These findings were ob-
tained using both low molecular weight inhibitors of the
two pathways and Ras effector mutants selectively activat-
ing these pathways. However, these mutants might signal
through additional pathways, which we did not assay for. To
study whether or not activation of the MAPK and PI3K
pathways was sufficient for EMT and tumor formation, re-
spectively, we are analyzing EpH4 cells expressing constitu-
tively active PI3K variants and Mek1–Erk fusion proteins
and an estrogen-inducible RafER fusion protein. Prelimi-
nary results suggest that RafER is not sufficient for EMT of
EpH4 cells in serum-free collagen gels (unpublished data)
in contrast to RafER-expressing MDCK cells, which un-
derwent EMT in serum-containing cultures upon RafER
activation (Lehmann et al., 2000). We currently analyze
whether RafER-EpH4 cells require both TGF  and basal
PI3K signaling induced by endogenous RTK ligands, both
obviously provided by serum.
So far, our studies did not address the role of the MAPK
and PI3K pathways in controlling proliferation of EpRas
cells either in collagen gels or in tumors. Our recent work re-
vealed that a moderate upregulation of the PI3K pathway
causes hyperproliferation of EpH4 cells in collagen gels and
rapid tumor growth but not EMT. In contrast, cells showing
a similarly upregulated MAPK pathway grow less rapid in
collagen gels and form only slowly growing tumors, which
nevertheless contained islands of mesenchymal tumor cells
having undergone EMT (unpublished data). This indicates
that tumor growth and EMT are controlled by independent
pathways and makes it very unlikely that the lack of in vivo
EMT in the C40-Ras–induced tumors is due to their
slightly slower growth rate as compared with respective S35-
Ras clones (Fig. 7 A).
Prevention of TGF -dependent growth
arrest/apoptosis without abolishing TGF -R signaling?
TGF  blocks cell cycle progression and causes apoptosis in
most normal epithelial cells, suggesting that an important
step in carcinogenesis is to overcome this antiproliferative ef-
fect of TGF  (Fynan and Reiss, 1993). Multiple human tu-
mors indeed carry inactivating mutations in Smad4 (Schutte
et al., 1996) or even TGF -RII (Parsons et al., 1995). How-
ever, complete suppression of TGF -R signaling by such tu-
mor suppressive mutations would also abolish the dominant
oncogenic effects of TGF , for example, EMT and metasta-
sis. This discrepancy is not yet fully explained by available
data. However, the rare tumors with TGF -RII mutations
have a low or absent ability to metastasize (Oft et al., 1998).
Furthermore, TGF  stimulation still induced a subset of
TGF -specific promoters in MEF’s from Smad4
 /  mice
(Sirard et al., 1998), suggesting that mammalian cells might
contain a second Smad4 family member already described in
frogs (Smad4 /Smad10) (Howell et al., 1999). Finally,
TGF -induced cell cycle arrest is also lost frequently by mu-
tations in downstream effectors like p16
ink4A/p15
ink4B (Hall
and Peters, 1996).
These results suggest that most carcinoma cells are se-
lected for resistance to TGF  cell cycle arrest while remain-
ing sensitive for induction of migration/invasion by TGF .
In line with this, murine and human cell lines completely re-
sistant to cell cycle arrest by TGF  retain apparently normal
TGF -R signaling (Oft et al., 1998; McEarchern et al.,
2001).
Obviously, oncogenic Ras completely substitutes for this
type of tumor cell selection in the various epithelial cell
models described above, including also strong protection
from TGF -induced apoptosis. However, possible mecha-
nisms for how Ras may modulate TGF -R signaling are still
controversially discussed. Ras signaling was reported to at-
tenuate Smad2/3 signaling via inhibitory phosphorylation,
preventing nuclear translocation (Kretzschmar et al., 1999),
but we and others failed to observe Ras-dependent inhibi-
tion of Smad2 or Smad3 nuclear translocation by elevated
Ras or Raf activity in several systems (Lehmann et al., 2000;
Liu et al., 2000). Therefore, the MAPK pathway might at-
tenuate TGF  responses via the induction and/or activation
of new distinct transcription factors, corepressors, or coacti-
vators recruited by Smads into a variety of transcriptional
modules, which determine the diversity of responses to simi-
lar TGF  signals in different cell types (Massague and Wot-
ton, 2000).
Metastasis: which EMT-related changes in gene 
expression are important?
The results presented here strongly correlate metastasis to
EMT, requiring cooperation of TGF -R–signaling with a
hyperactive MAPK pathway and thus arguing for a domi-
nant oncogenic role of the TGF -R pathway in addition to
possible tumor suppressive functions. This positive role of
TGF  in EMT and metastasis correlates best with the defect
of TGF -3
 /  mice in palate development (Taya et al.,
1999), which involves EMT, and by the defects in meso-
derm induction in mice lacking Smad4 or Smad2 (Wein-
stein et al., 1998; Yang et al., 1998).
Which TGF -induced gene expression changes are im-
portant for EMT? One clear example is the loss of E-cad-
herin typical for EMT, which has been implicated in tumor-
igenesis and metastasis (Christofori and Semb, 1999). In
line with this, the transcriptional repressor Snail blocks
E-cadherin expression and causes a fibroblastoid phenotype
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cinoma cell lines (Cano et al., 2000). However, mesenchy-
mal FosER cells after EMT completely lack E-cadherin but
form neither tumors nor metastases (Reichmann et al.,
1992), indicating that loss of E-cadherin expression may be
necessary but not sufficient for tumor progression.
Materials and methods
Cells and cell culture
The origin and culture conditions for EpH4 mouse mammary epithelial cells
and their Has-Ras–transformed derivative EpRas have been described earlier
(Reichmann et al., 1992; Oft et al., 1996). V12-Ras–, S35-Ras–, and C40-
Ras–expressing EpH4 cells were generated by retroviral gene transfer using
retroviral vectors of V12-Ras and its two mutants S35-V12–Ras and C40-
V12–Ras in pLXSN (Rodriguez-Viciana et al., 1997). Bcl-2–expressing cells
were generated as above by transfer of pBabe-puro Bcl-2 (a gift from M. Buss-
linger, Institute of Molecular Pathology). Construct DNA was used to trans-
fect cells from the Phoenix™ packaging cell line (grown in DME plus 10%
FCS and 2 mM glutamine, after recent hygromycin B/diphteria toxin selec-
tion for optimal virus production). After 2–3 d, virus supernatants from the
transfected packaging cells were used to infect EpH4, which were then se-
lected with 800  g/ml G418 (5–6 d) or 2  g/ml puromycin (3–4 d). Clones
were isolated from retrovirally infected and drug-selected cell populations
by seeding at low density, marking single adherent cells 8 h later, expansion
for 7–9 d, and isolation of colonies using trypsin-soaked filter paper circles.
Cells from mouse tumors were recultivated from finely minced tumors
by digestion in 2 mg/ml collagenase type VI (Sigma-Aldrich) plus 5% FCS
for 30 min. Dispersed cells were seeded in Eagle’s medium plus 15% FCS,
selected for 7 d in 800  g/ml G418 (day 2–8), and subcultured at a ratio of
1:3 every 2 d. During the first 2 d, 2 ng/ml TGF  were added to facilitate
outgrowth of ex-tumor cells.
Reagents and antibodies
10  g/ml stocks of recombinant TGF -1, acidic FGF-1, and HGF/SF (R &
D Systems) were prepared according to manufacturer’s instructions, that is,
FGF-1 solutions containing 1  g/ml of heparin. The PI3K and Mek-1 inhib-
itors LY294002 and PD98059 (Calbiochem) were kept as 20–50-mM
stocks in DMSO. The Ras farnesylation inhibitor L 739.749 (Kohl et al.,
1994; a gift from Dr. F. Himmelsbach, Boehringer, Ingelheim, Germany)
was kept as 10-mM stock solutions in DMSO at –70 C and refrozen di-
rectly after use. The following primary antibodies were used for immuno-
fluorescence: mouse anti–E-cadherin (C20820; Transduction Laboratories)
or polyclonal rabbit anti–E-cadherin (K84; a gift from R. Kemler, Max
Planck Institute of Immunobiology, Freiburg, Germany), monoclonal anti–
mouse vimentin, Vim-13.4 (V-2258; Sigma-Aldrich) or goat anti–mouse
Vimentin, C-20 (sc-7557; Santa Cruz Biotechnology, Inc.), rabbit poly-
clonal anti–integrin- 4 (sc-9090; Santa Cruz Biotechnology, Inc.), goat
polyclonal antimacrosialin/CD68 (sc-7084; Santa Cruz Biotechnology,
Inc.), and rabbit polyclonal antifibronectin (F-3648; Sigma-Alddrich), rab-
bit anti–ZO-1 (61–7300; Zymed Laboratories). The antibodies to detect
TGF -1, -2, and -3 by immunofluorescence have been described earlier
(Oft et al., 1996). Phospho-specific rabbit anti–phospho-Erk and anti–
phospho-Akt antibodies and antibodies detecting total Erk1/2 and Akt were
from New England Biolabs (9100 and 9270, respectivelty). Anti-pan Ras
Val-12 antibody with increased specificity to oncogenic V12-Ras was pur-
chased from Calbiochem (OP38).
Western blot analysis
Cells to be used for Western Blot analysis of either serine-phosphorylated
or total Erk and Ras proteins were 80% confluent and cultured in 4% FCS
or starved for 48 h (for phospho-Akt and total Akt). Plates were washed in
PBS and lysed on ice with kinase buffer (10 mM Tris, pH 7.6, 50 mM
NaCl, 1 mM EGTA, 1% Triton X-100, 50 mM NaF, 30 mM sodium pyro-
phosphate, 10 mM Na3VO4, 2 nM ocadoic acid, 10 mM Pefablock™ and
cocktail of protease inhibitors Complete™ both from Boehringer), centri-
fuged at 12,000 g  for 10 min at 4 C, and the pellet was discarded.
Freshly prepared lysates were analyzed by 8–10% SDS-PAGE and immu-
noblotted as described by others (Yu and Sato, 1999). Total V12-Ras ex-
pression was analyzed by 12% SDS-PAGE followed by Western Blot
analysis as above.
Collagen gel cultures
Serum-free three-dimensional cultures of EpH4 cells, EpRas cells, and their
derivatives were performed as described earlier (Oft et al., 1996, 1998)
with minor modifications. Cells (in serum-containing medium) and rat tail
collagen (3–4 mg/ml) (40236; Becton Dickinson) were mixed rapidly at
0 C (final collagen concentration 1.5 mg/ml), and 100- l droplets contain-
ing between 2,000 and 3,000 cells were dispensed into 17-mm wells.
When indicated, collagen solutions gels were supplemented with 10% vol/
vol Matrigel solution (GF reduced) (40 230; Becton Dickinson) directly be-
fore use. After solidification on a level surface at 23 C for 15–30 min, the
gels were incubated at 37 C in a CO2 incubator for another 1–2 h and
overlaid with 500  l of serum-free medium (mammary epithelial basal me-
dium) (C-21010; PromoCell GmbH) supplemented with growth factors ac-
cording to manufacturer’s instructions. The batches of bovine pituitary ex-
tract had to be pretested for optimal performance. The medium overlaying
the gel was changed 1 d after seeding and then every other day unless
stated otherwise.
After allowing structure formation of the cells for 4–7 d, growth factors
(20 ng/ml HGF, 20 ng/ml acidic FGF, and 5 ng/ml TGF  unless stated oth-
erwise) were added upon medium change every other day. Predetermined
amounts of pharmacological inhibitors (20% higher final concentrations to
correct for collagen gel volume) where added every 12 or 24 h for 5 d un-
less stated otherwise. Growth factors were withdrawn from collagen gels
by switching them to medium without factors, changing medium after 24 h,
and further cultivation for 2–5 d. In all experiments, at least 50–100 struc-
tures were inspected to quantify lumen-containing structures versus disor-
dered strands or chords. If  90% of the structures were of one type, quan-
tification is not further mentioned in the Results section.
Immunofluorescent staining and confocal microscopy 
of collagen gel structures
Collagen gels (sometimes split in half by a scalpel) were fixed with 1%
formaldehyde in 250 mM Hepes, pH 7.4, freshly diluted from 16% para-
formaldehyde stocks stored at –20 C. After 15 min at room temperature,
the gels were washed once each with Tris- and phosphate-buffered saline
plus 0.2% Tween 20 (TBST and PBST, respectively) and treated for 1 h at
4 C with blocking solution (PBST, 0.1% gelatin plus 10  g/ml nonimmune
bovine IgG). Gels were incubated with primary antibodies plus DAPI in
blocking solution for 1 h at 37 C in a wet chamber, washed three times in
PBST for 30 min, and postfixed with 4% PFA in PBST for 15 min at 23 C.
After 30-min washes in TBST, PBST, and blocking solution, the gels were
incubated with appropriate secondary antibody mixtures made up in
blocking solution for at least 1 h or overnight at 4 C. Gels were washed
three times in PBS, once in distilled water, and mounted in Mowiol
(Hoechst). Confocal analysis was performed using a Leica TCS-NT confo-
cal microscope (DAPI visualized by two-photon excitation microscopy us-
ing Coherent-Vitesse pulsed NIR laser). From representative gel structures,
5–10 horizontal scans using a 40  (1.3 NA) oil immersion objective were
recorded for each channel and used to calculate an extended focus image
with the respective software (exported as a TIFF file).
Cryo-sectioning and immunofluorescent 
staining of collagen gel structures
Cryo-sectioning was performed to visualize TGF  and ZO-1 by antibody
staining not possible using whole-mount gels. Collagen gels were fixed for
15 min at 4% PFA in 250 mM Hepes followed by 8% PFA in 250 mM
Hepes for 1 h and then washed in TBS. Individual structures were excised
from the gel under a dissection microscope and placed into PVP/sucrose
(Sigma-Aldrich) on ice. Blocks were incubated in PVP/sucrose overnight,
mounted upright onto a cryo-nail, flash-frozen in liquid nitrogen, and
stored in liquid nitrogen until further use. For sectioning, these nails were
placed into a Leica Cryo-Microtome and semi-thin sections of 500–800
nm were placed on a gelatin-coated slide. Alternatively, ultrathin sections
of 100–130 nm were placed on copper grids for EM analysis. Immuno-
staining of semi-thin sections was performed in small drops on the slides
directly with the same solutions as mentioned above for whole-mount
stainings. Samples were analyzed by conventional fluorescent microscopy,
recorded with a monochrome digital camera, and the three channel color
image was restored from the individual images.
Immuofluorescence of cells grown on porous supports
Cells were cultivated on porous supports (cell culture inserts, pore size 0.4
 m; Becton Dickinson) for 2–7 d and fixed either at  70% confluency (or
as fully confluent well-polarized epithelial sheets). Filters were rinsed
twice with Hank’s solution plus glucose or PBS, fixed in acetone/methanol
(1:1) for 5 min at –20 C, dried, washed with PBS, and blocked for 1 h in
0.2% gelatin in PBS-containing nonimmune goat or bovine IgGs (20  g/
ml) and 0.05% Tween. Filters were then incubated with first antibody (di-
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times in PBS containing 0.05% Tween, treated with similarly prepared di-
lutions of secondary antibodies for 30 min, and washed again as above
(first wash containing DAPI; 1 mg/ml stock, final dilution 1:10,000). Alexa-
conjugated secondary antibodies against rabbit or mouse IgG (Molecular
Probes, Inc.) were diluted 1:1,000, whereas Cy3-conjugated goat anti–rab-
bit or anti–mouse IgG (Jackson ImmunoResearch Laboratories) were di-
luted 1:300. Confocal microscopy was performed as above, recording only
single horizontal scans for each channel.
Apoptosis assays using cells and structures from collagen gels
2–3 d after seeding, cell structures within collagen gels were treated with
TGF  plus or minus other factors/inhibitors for 2.5 or 4 d. After washing in
PBS, the structures were either processed to yield cell suspensions or
TUNEL stained in situ. To generate and stain cell suspensions, collagen
gels were digested with 2 mg/ml collagenase in 0.5 ml PBS for 10 min.
Pooled cells from 8 gels were spun down, washed in PBS, transferred into
v-shaped wells of a 96-well plate, fixed with 4% PFA for 1 h, treated with
0.1% Triton X-100 in 0.1% sodium citrate and subjected to the TUNEL as-
say (method for cells in suspension) (1684795; Roche) according to manu-
facturer’s instructions. After staining with DAPI in the last wash, TUNEL-
stained cell pellets were suspended in 30  l Mowiol, spread on glass
slides, and apoptotic indices were determined by counting green versus
blue nuclei under the fluorescence microscope. For each point, at least
500 cells were scored. Mean values and SD were calculated from three in-
dependent determinations.
For TUNEL staining of collagen gels in situ, the collagen gels were fixed
with 4% PFA for 2 h, washed in PBS, and subjected to the TUNEL assay (as
above) according to the manufacturer’s instructions for tissue sections with
minor modifications. Briefly, 65  l of reaction mix diluted 1:1 in PBS was
added to each collagen gel in 17-mm wells, and the wells were then cov-
ered with parafilm and incubated at 37 C for 2.5 h. Subsequently, labeled
collagen gels were washed three times in PBS and once with HBS contain-
ing DAPI. Collagen gels were spread on slides, mounted in Mowiol, and
TUNEL-positive cells (FITC-labeled) were scored against DAPI-stained nu-
clei under a fluorescence microscope (counting  1,000 cells from three to
six randomly chosen fields in two to three collagen gels). Mean apoptotic
indices   SD are shown.
Trypan blue exclusion assay
4 d after the start of inhibitor treatment, collagen gels were rinsed in PBS,
incubated 5 min in 0.5 ml trypan blue solution 0.4% (T 8154; Sigma-
Aldrich), and rinsed twice in PBS. Thereafter, the percentage of stained
structures was determined under a bright field microscope, counting at
least 100 structures (“partially dead” and “dead” structures containing 25–
60% or  60% cells of trypan blue–positive cells).
Induction of tumors and metastases in mice
To test the various cell types for tumorigenicity, groups of three to six
BalbC athymic nude mice (nu/nu; 5–9 wk old; obtained from Charles River
Wiga, GmbH, Sulzfeld, Germany) were used for each cell type per experi-
ment. Confluent cells from several V12-Ras, S35-Ras, and C40-Ras clones
were trypsinized and washed three times in PBS. Multiple doses of 10
5
cells suspended in 25  l PBS were injected into the 3rd and 4th mammary
gland pairs of Metofane anaesthetized mice (shallow injection into the nip-
ple area). Initial tumor nodules were confined to the mammary fat pad in
almost all cases. Primary tumor growth was weekly measured with a cali-
per in mm. Mean tumor diameter was calculated as the sum of diameters
of all tumors detected divided by the number of injection sides. For the ex-
perimental metastasis assay, 10
5 ex-tumor cells derived from tumors in-
duced by the above clones (as described in Cells and cell culture) were
suspended in 100  l PBS and injected into the tail veins of MF1 nu/nu
mice (Charles River Wiga, GmbH). Lethality of injection due to lung me-
tastasis was assessed daily, and freshly dead or moribund mice were pro-
cessed for histopathological analysis. For this, lungs were fixed in PFA
3.7% in PBS, postfixed with 70% EtOH, and embedded in paraffin. Sec-
tions were cut at 7.5- m steps and stained with hematoxylin and eosin ac-
cording to standard protocols. The surviving mice were killed after 10 wk,
inspected visually for metastases in major organs, and the lungs were sub-
jected to histological analyses as above.
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